Compare BOX & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOX | PTCT |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.3B |
| IPO Year | 2015 | 2013 |
| Metric | BOX | PTCT |
|---|---|---|
| Price | $30.60 | $77.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 17 |
| Target Price | $38.67 | ★ $73.76 |
| AVG Volume (30 Days) | ★ 2.3M | 1.3M |
| Earning Date | 12-02-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.13 | N/A |
| EPS | 1.24 | ★ 8.94 |
| Revenue | $1,150,898,000.00 | ★ $1,779,150,000.00 |
| Revenue This Year | $9.07 | $127.32 |
| Revenue Next Year | $7.74 | N/A |
| P/E Ratio | $24.27 | ★ $8.78 |
| Revenue Growth | 7.21 | ★ 97.54 |
| 52 Week Low | $28.00 | $35.95 |
| 52 Week High | $38.80 | $87.50 |
| Indicator | BOX | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 51.28 | 53.66 |
| Support Level | $29.42 | $77.18 |
| Resistance Level | $30.69 | $80.20 |
| Average True Range (ATR) | 0.58 | 2.17 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 56.80 | 62.03 |
Box is a cloud-based content management platform that provides storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file, sync, and share provider. Over time, it built out and acquired workflow and security tools to evolve the pure-play FSS business into a content management business. Most recently, Box has been pursuing an AI-powered, intelligent content management strategy that can allow for metadata extraction and workflow automation.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.